Pfizer Gets Global Rights to Three Starna In Vivo CAR-T Therapies
· 1 sources
Pfizer secures rights outside Greater China to three preclinical in vivo CAR-T therapies from Starna Therapeutics, MedCity News reports.
What happened
Pfizer has obtained global rights, excluding Greater China, to three in vivo CAR-T cell therapies from Starna Therapeutics, MedCity News reports. The deal extends Pfizer's immunology strategy into in vivo cell therapy.
According to MedCity News, the three therapies are in preclinical development and target autoimmune diseases that have not been disclosed. The outlet describes the agreement as the latest in a series of large pharmaceutical deals involving in vivo cell therapy assets and platform technologies.
Context
In vivo CAR-T approaches aim to engineer immune cells inside the patient's body rather than modifying them outside it first.
Why it matters
The deal shows how a large drugmaker like Pfizer is positioning in the growing field of in vivo cell therapy for autoimmune conditions.
Stocks in this story
Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.
$36.82Fair range: $29.63 to $70.73The price ($28.06) is 23.8% below that figure.
Chance of a rise in 1 month
52%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $27.06 and $29.31; 9 in 10, between $25.21 and $31.46.
Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.
Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer
ATLAS Signals
ATLAS Signals, every week
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy